(0.24%) 5 144.00 points
(0.19%) 38 513 points
(0.33%) 17 905 points
(-0.51%) $83.42
(1.98%) $1.961
(0.03%) $2 348.00
(0.32%) $27.62
(0.88%) $930.25
(-0.20%) $0.933
(-0.29%) $10.99
(-0.33%) $0.798
(1.14%) $92.93
Live Chart Being Loaded With Signals
Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States...
Stats | |
---|---|
Šios dienos apimtis | 17 511.00 |
Vidutinė apimtis | 43 130.00 |
Rinkos kapitalizacija | 677 686 |
EPS | $0 ( 2024-03-29 ) |
Kita pelno data | ( $0 ) 2024-06-06 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.0600 |
ATR14 | $0 (0.00%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-10-13 | Puissance Capital Management Lp | Sell | 1 076 841 | Common Stock |
2023-06-07 | Amin Naseem | Buy | 47 578 | Common Stock |
2023-06-07 | Fernandes Peter | Sell | 100 000 | Stock Options (Right to Buy) |
2023-06-07 | Shah Parag Suresh | Sell | 50 000 | Stock Options (Right to Buy) |
2023-06-07 | Dekker Martin | Sell | 50 000 | Stock Options (Right to Buy) |
INSIDER POWER |
---|
-74.13 |
Last 99 transactions |
Buy: 6 532 145 | Sell: 5 633 542 |
Bellerophon Therapeutics Koreliacija
10 Labiausiai teigiamai susiję koreliacijos | |
---|---|
CPTA | 0.936 |
SGEN | 0.934 |
RETA | 0.929 |
ORTX | 0.928 |
NVCT | 0.924 |
XLRN | 0.922 |
DUOL | 0.92 |
FLMN | 0.919 |
LMB | 0.919 |
RELY | 0.918 |
10 Labiausiai neigiamai susiję koreliacijos | |
---|---|
CMLS | -0.959 |
JRJC | -0.949 |
AADI | -0.947 |
CPTN | -0.944 |
MICS | -0.942 |
IHRT | -0.942 |
MDRX | -0.942 |
EYE | -0.941 |
ESSA | -0.94 |
SILK | -0.938 |
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
Bellerophon Therapeutics Finansinės ataskaitos
Annual | 2022 |
Pajamos: | $0 |
Bruto pelnas: | $0 (0.00 %) |
EPS: | $-2.08 |
FY | 2022 |
Pajamos: | $0 |
Bruto pelnas: | $0 (0.00 %) |
EPS: | $-2.08 |
FY | 2021 |
Pajamos: | $0.00 |
Bruto pelnas: | $0.00 (0.00 %) |
EPS: | $-1.870 |
FY | 2020 |
Pajamos: | $0.00 |
Bruto pelnas: | $0.00 (0.00 %) |
EPS: | $-3.17 |
Financial Reports:
No articles found.
Bellerophon Therapeutics
Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its product includes INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension. The company engages in the development of INOpulse that is in Phase 3 clinical trial for the treatment of pulmonary hypertension associated with fibrotic interstitial lung disease; which has completed Phase 2a clinical trial for pulmonary hypertension associated with chronic obstructive pulmonary disease; and that has completed Phase 2 dose escalation stage for pulmonary hypertension associated with sarcoidosis, as well as for chronic thromboembolic pulmonary hypertension and pulmonary hypertension associated with pulmonary edema from high altitude sickness. The company was formerly known as Ikaria Development LLC and changed its name to Bellerophon Therapeutics, Inc. in January 2014. Bellerophon Therapeutics, Inc. was founded in 2009 and is headquartered in Warren, New Jersey.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.